Daniel Lax

Director, Pediatric Headache

Montefiore Medical Center
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Daniel Lax is the Director of Pediatric Headache at Montefiore Medical Center, located in the United States. His research primarily focuses on pediatric neurology, with recent publications addressing topics such as pediatric concussion, diagnostic approaches to headaches, and management strategies for chronic migraines in children and adolescents. He has also explored specialized cases related to headache syndromes and neurological disorders in pediatric patients.

Articles (8)

Year:

2025

Year:

2023

Year:

2023

Background Degree of cerebrovascular stenosis in pediatric patients with sickle cell anemia (SCA) informs need for chronic transfusion therapy, which has significant risks. Flow artifact, intrinsic to magnetic resonance angiography (MRA), is dependent on technical parameters and can lead to overinterpretation of stenosis. The primary objective of this study was to document any change in stroke prevention therapy that could be attributed to the implementation of a standardized MRA scanning protocol for patients with SCA. Methods A standardized MRA scanning protocol with an echo time of less than 5 ms was implemented at Montefiore Medical Center (MMC), NY in May 2016. Retrospective chart review identified 21 pediatric patients with SCA, with an MRA head both pre‐ and post‐May 2016. Arterial stenosis on MRA, machine parameters, and treatment plans were compared pre‐ and post‐implementation. Results Ten of the 21 patients met inclusion criteria. Previously seen stenosis was re‐classified to a lower degree in six of the 10 patients, leading to discontinuation of transfusions in five patients. No patients required escalation of therapy to chronic transfusions. Conclusion Optimizing flow artifact by decreasing echo time to less than 5 ms can improve accurate interpretation of cerebrovascular disease, and ensure appropriate treatment plans are in place for stroke prevention. This is especially important for implementing “TCD With Transfusions Changing to Hydroxyurea (TWiTCH)” clinical trial results in the real‐world setting.

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (2)

Andrew D. Hershey

-

UNITED STATES
View details

William Mitchell

-

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.